Patients across the United Kingdom will continue to benefit from access to medical devices and in vitro diagnostic (IVD) products bearing the European Union’s CE mark, following a decision by the UK government to grant indefinite recognition to CE-marked products. Announced on 21 October after a public consultation held between February and April 2026, the measure is designed to simplify market access while ensuring continuity of supply for healthcare providers and patients. Under the new framework, devices already approved under EU regulations will be able to continue entering the UK market without undergoing additional approval procedures. The government says the move will help accelerate patient access to innovative health technologies while reducing unnecessary regulatory burdens for manufacturers, distributors and importers.
Greater certainty for patients and industry
According to the UK regulatory agency MHRA, more than 90% of devices currently registered in the country carry CE marking. The long-term recognition policy is intended to provide greater certainty for both industry and patients and will operate alongside the UK’s domestic UKCA marking system, which remains applicable to devices placed on the market in Great Britain. The decision is also aligned with MHRA’s 2030 strategy, which seeks to expand the use of international reliance mechanisms and increase recognition of decisions issued by trusted regulatory authorities. By leveraging established regulatory assessments, the agency aims to maintain high safety standards while reducing duplication and supporting innovation.
No additional approval requirements
One of the most significant consequences of the measure is that manufacturers will no longer face the prospect of duplicative assessment pathways for products that have already obtained CE certification in the European Union. The government expects the move to streamline regulatory processes, ease market access and reduce administrative burdens across the sector. At the same time, healthcare providers and patients are expected to benefit from faster and more reliable access to medical technologies already available within the European market.
Industry associations welcome the move
The announcement has been positively received by industry stakeholders, including MedTech Europe, the Association of British HealthTech Industries (ABHI) and the British In Vitro Diagnostics Association (BIVDA). In a joint statement, the three organisations described the decision as an important milestone in the ongoing reform of the UK’s regulatory system. The associations highlighted the highly integrated nature of the European and British medical technology sectors, characterised by interconnected supply chains, cross-border trade and close regulatory cooperation.
A step towards regulatory convergence
According to the industry groups, indefinite recognition of CE marking represents a pragmatic and proportionate approach to maintaining high standards of safety and performance while supporting innovation, investment and competitiveness on both sides of the Channel. The organisations also stressed the importance of continued regulatory convergence between the United Kingdom and the European Union, arguing that alignment can help ensure efficient market access while preserving robust patient protections and fostering long-term growth across the medical technology sector. For manufacturers operating internationally, the decision is expected to provide greater regulatory predictability and reinforce the UK’s attractiveness as a destination for medical technology development and commercialization.